For WB analysis of the effects of CDC6si, ARsi, TOPBP1si, AZD7762 and combinations of them, cells were transfected with siRNA for 24 hours and then, treated with DMSO or AZD7762 for 24 hours. Afterward, cells were treated with a serum-free medium overnight and then with full serum for 4 hours (synchronization) before protein extract preparation. For WB analysis of ENZ and AZD7762 effects, cells were treated with DMSO or ENZ for 24 hours. DMSO or AZD7762 was then added for 24 hours. Synchronization was achieved as above. Antibodies against CDC6 (3387), ATR (2790), P-ATR Ser428 (2853), Chk1 (2360), P-Chk1Ser317 (12302), Cdc25C (4688), P-Cdc25C Ser216 (9528), ATM (2873), P-ATM Ser1981 (13050) were purchased from Cell Signaling Technology. Antibodies against P-CDC6 Ser54 (ab75809), P-Chk1ser296 (
ab79758), and TopBp1 (
ab2402) were purchased from Abcam. Antibodies against GAPDH (365062) and AR (816) were purchased from Santa Cruz Biotechnology. When indicated, densitometric analysis was performed and quantification of integrated density was assessed using the
NIS-Elements-AR software program (version 3.0; Nikon) followed by GAPDH normalization.
Karanika S., Karantanos T., Li L., Wang J., Park S., Yang G., Zuo X., Song J.H., Maity S.N., Manyam G.C., Broom B., Aparicio A.M., Gallick G., Troncoso P., Corn P.G., Navone N., Zhang W., Li S, & Thompson. T.C. (2017). Targeting DNA damage response in prostate cancer through inhibition of androgen receptor/CDC6-ATR-Chk1 signaling: Combined AR/CDC6 and Chk1/2 inhibition for PCa. Cell reports, 18(8), 1970-1981.